CN114072376B - 用于预防和治疗肥胖和有关障碍的化合物 - Google Patents

用于预防和治疗肥胖和有关障碍的化合物 Download PDF

Info

Publication number
CN114072376B
CN114072376B CN202080030234.4A CN202080030234A CN114072376B CN 114072376 B CN114072376 B CN 114072376B CN 202080030234 A CN202080030234 A CN 202080030234A CN 114072376 B CN114072376 B CN 114072376B
Authority
CN
China
Prior art keywords
subject
certain embodiments
day
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080030234.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114072376A (zh
Inventor
E·J·维拉弗兰卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abrex Pharmaceutical Co ltd
Original Assignee
Abrex Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abrex Pharmaceutical Co ltd filed Critical Abrex Pharmaceutical Co ltd
Publication of CN114072376A publication Critical patent/CN114072376A/zh
Application granted granted Critical
Publication of CN114072376B publication Critical patent/CN114072376B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080030234.4A 2019-03-01 2020-03-02 用于预防和治疗肥胖和有关障碍的化合物 Active CN114072376B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812314P 2019-03-01 2019-03-01
US62/812,314 2019-03-01
PCT/US2020/020707 WO2020180821A1 (en) 2019-03-01 2020-03-02 Compounds for prevention and treatment of obesity and related disorders

Publications (2)

Publication Number Publication Date
CN114072376A CN114072376A (zh) 2022-02-18
CN114072376B true CN114072376B (zh) 2024-12-20

Family

ID=72338080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030234.4A Active CN114072376B (zh) 2019-03-01 2020-03-02 用于预防和治疗肥胖和有关障碍的化合物

Country Status (7)

Country Link
US (1) US12357596B2 (https=)
EP (1) EP3931179B1 (https=)
JP (1) JP7598195B2 (https=)
CN (1) CN114072376B (https=)
CA (1) CA3132318A1 (https=)
ES (1) ES3059224T3 (https=)
WO (1) WO2020180821A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024249415A1 (en) * 2023-05-26 2024-12-05 Abrexa Pharmaceuticals, Inc. Compounds for use in organ preservation and organ transplantation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017540A (en) * 1968-03-04 1977-04-12 The Upjohn Company Method of use, composition, and compounds
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20070238700A1 (en) * 2006-04-10 2007-10-11 Winzenberg Kevin N N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
US8779002B2 (en) * 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
WO2017112701A1 (en) * 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same

Also Published As

Publication number Publication date
EP3931179A1 (en) 2022-01-05
CN114072376A (zh) 2022-02-18
WO2020180821A1 (en) 2020-09-10
ES3059224T3 (en) 2026-03-19
CA3132318A1 (en) 2020-09-10
EP3931179C0 (en) 2025-12-10
US12357596B2 (en) 2025-07-15
EP3931179A4 (en) 2022-11-30
US20220133657A1 (en) 2022-05-05
JP2022523792A (ja) 2022-04-26
JP7598195B2 (ja) 2024-12-11
EP3931179B1 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
AU2014340182B2 (en) Cromolyn derivatives and related methods of imaging and treatment
CN106999462B (zh) 包含选择性s1p1受体激动剂的药物组合物
JPH03232816A (ja) シロップ剤組成物
EP3931178B1 (en) Compounds for prevention and treatment of post-operative cognitive dysfunction
BRPI0922806B1 (pt) Composição farmacêutica oral compreendendo bendamustina
MXPA03003150A (es) Soluciones farmaceuticas de compuestos de modafinilo.
JP7740810B2 (ja) 呼吸困難に起因する集中治療後の認知機能障害及び認知障害の予防及び治療のための化合物
CN114072376B (zh) 用于预防和治疗肥胖和有关障碍的化合物
US11938104B1 (en) Compositions and methods for prevention and treatment of coronavirus and related disorders
CN116348445B (zh) 用于预防和治疗出血和脉管系统不稳定的化合物
WO2024249415A1 (en) Compounds for use in organ preservation and organ transplantation
US11931370B2 (en) Stable pharmaceutical compositions of cyclophosphamide
EP4547244A1 (en) Scd1 inhibitors for treating liver disease
HK40089435A (zh) 预防和治疗重症监护後认知功能障碍和呼吸窘迫致认知功能障碍的化合物
JPH0459729A (ja) 肝障害抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant